KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Current Assets Current Deferred Tax Assets Current Taxes Dividends payables Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Eli Lilly (LLY) Liabilities from Discontinued Operations (2018)

Historic Liabilities from Discontinued Operations for Eli Lilly (LLY) over the last 1 years, with Q4 2018 value amounting to $2.7 billion.

Eli Lilly's Liabilities from Discontinued Operations changed N/A to $2.7 billion in Q4 2018 from the same period last year, while for Dec 2018 it was $2.7 billion, marking a year-over-year change of. This contributed to the annual value of $2.7 billion for FY2018, which is N/A changed from last year.
Per Eli Lilly's latest filing, its Liabilities from Discontinued Operations stood at $2.7 billion for Q4 2018.
Eli Lilly's 5-year Liabilities from Discontinued Operations high stood at $2.7 billion for Q4 2018, and its period low was $2.7 billion during Q4 2018.